SCHEMBL23342007

SCHEMBL23342007

CC(C)C(=O)N1CCC2(CC1)CCN(C(C)C)C2=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC2 O75106 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
RIPK1 Q13546 2/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
CHRNB3 Q05901 1/20 0.33
CHRNA6 Q15825 1/20 0.33
MTNR1B P49286 1/20 0.32
PRMT1 Q99873 2/20 0.32
ITGB3 P05106 2/20 0.32
ITGA2B P08514 2/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
POLB P06746 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23342178 0.90 CRBN (0.36) AOC2L3MBTL1RIPK1CHRNB2CHRNA3
SCHEMBL23338590 0.89 ACACB (0.33) AOC2RIPK1CHRNB2CHRNA3CHRNA4
SCHEMBL23342004 0.83 ACACB (0.38) AOC2RIPK1ACACBACACAMMP2
SCHEMBL24339062 0.81 GRIN2B (0.41) OPRD1OPRK1ITGB3ITGA2B
SCHEMBL23342003 0.80 ACACB (0.34) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL13431755 0.78 PRMT1 (0.37) AOC2OPRD1OPRK1PRMT1ACACB
SCHEMBL12026643 0.77 CYP2D6 (0.39) AOC2OPRD1OPRK1PRMT1POLB
SCHEMBL21061534 0.77 PRMT1 (0.37) AOC2OPRD1OPRK1PRMT1ACACB
SCHEMBL12049830 0.77 CHRM2 (0.43) AOC2PRMT1
SCHEMBL25919762 0.76 NOTUM (0.31) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-20210130326-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739074-B2 Ras inhibitors KRAS, NRAS, HRAS AOC2 4440/4885L3MBTL1 3587/4885RIPK1 1490/4885
US-20210130326-A1 RAS INHIBITORS KRAS, NRAS, HRAS AOC2 4551/4885L3MBTL1 3097/4885RIPK1 819/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR AOC2 4449/4885L3MBTL1 1005/4885RIPK1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.